Adjuvanted varicella zoster vaccine - Dynavax Technologies
Alternative Names: Adjuvanted varicella zoster virus recombinant vaccine - Dynavax Technologies; Chickenpox vaccine - Dynavax Technologies; Z-1018Latest Information Update: 03 Jul 2024
At a glance
- Originator Dynavax Technologies
- Class Synthetic vaccines; Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Herpes zoster
- Phase I Varicella zoster virus infections
Most Recent Events
- 27 Jun 2024 Phase-I/II clinical trials in Herpes zoster (Prevention) in Australia (Parenteral)
- 08 May 2024 Dynavax plans to initiate a phase I/II trial for adjuvanted varicella zoster vaccine in Varicella zoster virus infections (Prevention) (Parenteral) in the second quarter of 2024
- 31 Mar 2024 US FDA approves IND application for Adjuvanted varicella zoster vaccine in Varicella zoster virus infections (Prevention)